Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy.

diabetes euglycemic diabetic ketoacidosis sodium‐glucose cotransporter 2 inhibitors

Journal

Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 14 09 2021
revised: 22 10 2021
accepted: 26 10 2021
entrez: 17 11 2021
pubmed: 18 11 2021
medline: 18 11 2021
Statut: epublish

Résumé

Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half-lives, the typical duration used to guide pre-operative medication recommendations.

Identifiants

pubmed: 34786197
doi: 10.1002/ccr3.5057
pii: CCR35057
pmc: PMC8577244
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e05057

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

No conflicts of interest.

Références

Diabetes Metab. 2019 Oct;45(5):453-457
pubmed: 30639566
Clin Diabetes. 2020 Jan;38(1):112-116
pubmed: 31975762
Diabetes Care. 2015 Sep;38(9):1687-93
pubmed: 26078479
Intern Med. 2017;56(2):187-190
pubmed: 28090050
Clin Pharmacokinet. 2015 Oct;54(10):1027-41
pubmed: 26041408
Diabetes Res Clin Pract. 2016 Aug;118:77-8
pubmed: 27351797
BMJ Case Rep. 2020 Oct 7;13(10):
pubmed: 33028568
Endocrinol Diabetes Metab Case Rep. 2019 Sep 27;2019:
pubmed: 31600728
AACE Clin Case Rep. 2020 Dec 28;7(1):17-19
pubmed: 33851013
Sci Rep. 2021 May 13;11(1):10293
pubmed: 33986421
Am J Kidney Dis. 2017 Jun;69(6):A11-A13
pubmed: 28532637
Diabetes. 2012 Sep;61(9):2199-204
pubmed: 22923645
J Investig Med High Impact Case Rep. 2017 May 24;5(2):2324709617710040
pubmed: 28589154
Diabetes Care. 2015 Sep;38(9):1638-42
pubmed: 26294774
Clin Case Rep. 2021 Nov 09;9(11):e05057
pubmed: 34786197
Adv Chronic Kidney Dis. 2010 Jul;17(4):302-7
pubmed: 20610357
J Investig Med High Impact Case Rep. 2017 Jun 08;5(2):2324709617712736
pubmed: 28634592
Endocrinol Diabetes Metab Case Rep. 2018 Jun 06;2018:
pubmed: 29899991
J Clin Pharmacol. 2015 Sep;55(9):1061-72
pubmed: 25827774
Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220
pubmed: 33298426
Clin Pharmacol Drug Dev. 2017 Sep;6 Suppl 1:3-72
pubmed: 28862797
Int J Emerg Med. 2020 Jan 22;13(1):2
pubmed: 31969112
Endocrinol Diabetes Metab. 2020 Feb 29;3(2):e00117
pubmed: 32318635

Auteurs

David Bobrowski (D)

Department of Medicine University of Toronto Toronto Ontario Canada.

Reha Kumar (R)

Department of Medicine University of Toronto Toronto Ontario Canada.

Peter E Wu (PE)

Department of Medicine University of Toronto Toronto Ontario Canada.
Division of Clinical Pharmacology & Toxicology University of Toronto Toronto Ontario Canada.

Lauren Lapointe-Shaw (L)

Department of Medicine University of Toronto Toronto Ontario Canada.
Division of General Internal Medicine and Geriatrics University Health Network Toronto Ontario Canada.

Classifications MeSH